Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,747.78
(
0.72%
)
US TECH 100
24,132.80
(
0.49%
)
Dow Jones
47,389.52
(
0.94%
)
Brent Oil
99.20
(
0.91%
)
Bitcoin
73,848.20
(
-1.32%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

exwannabe

Send PM Follow Ignore
Followers 91
Posts 20550
Boards Moderated 0
Alias Born 09/06/2006

exwannabe

Re: DewDiligence post# 83011

Sunday, 08/30/2009 7:49:25 PM

Sunday, August 30, 2009 7:49:25 PM

Post# of 257251
Re: SNY’s Otamixaban Is Unimpressive ..

"SEPIA-ACS1 study showed that otamixaban displayed clinically meaningful activity on the primary endpoint from the threshold dose of 0.070 mg/kg/h, the second tested dose, with a consistent antithrombotic effect up to the 5th highest tested dosage."

OK, am I brain dead or anal on questioning what this says?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now